Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors.
Wednesday, June 19, 2024
Dr. Minal Barve
View the abstract via the above link.
![ASCO Poster for Trial 20-13](https://marycrowley.org/wp-content/uploads/2024/06/Poster-8.jpg)
ASCO 2024 Poster for Trial 20-13